Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials.
WALTHAM, Mass., March 5, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a solid tumor targeting TriNKET®.
ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly's platform technology to enter the clinic, and the first AbbVie-licensed TriNKET® drug candidate to enter into the clinic. The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie's budigalimab (ABBV-181), in solid tumors.
"We are delighted that AbbVie has advanced ABBV-303 into the clinic," said Bill Haney, CEO and Dragonfly co-founder. "AbbVie is a global leader in advancing novel treatments for some of the most complex diseases and a terrific partner. We look forward to continued success and rapid progress with the AbbVie team to advance potential new treatment options for patients."
Additional information about the M24-122 Phase 1 trial, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT06158958).
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing novel therapies that harness the body's immune system to bring breakthrough treatments to patients. In addition to a set of advanced programs in the clinic, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platforms that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit:www.dragonflytx.comhttps://www.linkedin.com/company/dragonfly-therapeutics-inc./https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne E. Deconinck | anne@dragonflytx.com
SOURCE Dragonfly Therapeutics, Inc.
Thank u
The announcement that Dragonfly will present preclinical data on DF6215 and DF9001 at SITC reflects exciting progress in immunotherapy research. These innovative therapies, including an IL-2R alpha-active agonist and an EGFR-targeting TriNKET®, show strong potential in advancing targeted cancer treatment. Such developments highlight how biotechnology continues to push boundaries, offering hope for more effective and personalized therapies. In a similar way, industries evolve with precision and innovation—just like embroidery digitizing services, where advanced techniques transform complex designs into accurate stitch patterns. Both fields demonstrate how technology and expertise can create impactful, high-quality results for the future.
I found this article informative and practical for everyday router users. People researching 1.0.0.0.1 can benefit from learning that router addresses vary depending on the device. Checking the correct gateway before logging in is important, while clear guidance can help users navigate configuration settings and resolve simple access issues.
It’s really encouraging to see Dragonfly hit another milestone, especially with this being the eighth platform drug to reach the clinic and the first AbbVie-licensed TriNKET to be dosed. The solid tumor space needs more novel approaches like this, so I’ll be watching the Phase 1 data with interest. By the way, I keep a supplier of construction wire, tie wire, rebar supports, anchor bolts and temporary fencing for importers and distributors I like to share: https://www.leeter.cn/resources/welded-wire-mesh-suppliers-in-china/
Consultar los resultados después de un sorteo es mucho más fácil cuando los números aparecen correctamente organizados. Pick 5 es una búsqueda útil para encontrar las combinaciones correspondientes y comprobar si los números seleccionados coinciden con alguno de los resultados anunciados.